ESMO 2018 | The omega score: an emerging biomarker for risk determination

Hisham Mehanna

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, FRCS(ORL-HNS), of the University of Birmingham, Birmingham, UK, reflects on an interesting biomarker study suggesting a role for the omega score as a clinical classifier of risk of death due to the tumor vs. other causes in cancer patients. Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Prof. Mehanna, further explores the potential clinical application of omega in patient selection for treatment intensification, before discussing the results from a current clinical trial investigating a combination of monalizumab and cetuximab in recurring metastatic cancer patients.

Share this video